These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29772540)

  • 1. Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer.
    Kumar S; Gurshaney S; Adagunodo Y; Gage E; Qadri S; Sharma M; Malik S; Manne U; Singh UP; Singh R; Mishra MK
    Front Biosci (Landmark Ed); 2018 Jun; 23(11):1987-2000. PubMed ID: 29772540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assays for prostate cancer : changing the screening paradigm?
    Hansen J; Rink M; Graefen M; Shariat S; Chun FK
    Mol Diagn Ther; 2013 Feb; 17(1):1-8. PubMed ID: 23355098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein.
    Akino H; Suzuki Y; Oyama N; Kanamaru H; Okada K
    Int J Urol; 1999 Sep; 6(9):440-5. PubMed ID: 10510889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of gamma-seminoprotein in combination with prostate specific antigen in detecting prostate cancer.
    Nakashima J; Nagata H; Sumitomo M; Miyajima A; Tachibana M; Baba S; Jitsukawa S; Murai M
    Int J Urol; 1999 Jun; 6(6):298-304. PubMed ID: 10404306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.
    Abe M; Manola JB; Oh WK; Parslow DL; George DJ; Austin CL; Kantoff PW
    Clin Prostate Cancer; 2004 Jun; 3(1):49-53. PubMed ID: 15279691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
    Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia].
    Kamalov AA; Samokhodskaya LM; Karpov VK; Okhobotov DA; Mamedov VN
    Urologiia; 2019 Jun; (2):73-81. PubMed ID: 31162906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
    Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
    Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Screening.
    Catalona WJ
    Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3: a possible complementary marker to the PSA blood test.
    Balan V; Wang Y; Nangia-Makker P; Kho D; Bajaj M; Smith D; Heilbrun L; Raz A; Heath E
    Oncotarget; 2013 Apr; 4(4):542-9. PubMed ID: 23625538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
    Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
    PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml].
    Demura T; Ohyama I; Togashi M; Ohashi N; Chikaraishi T; Hirano T; Koyanagi T
    Nihon Hinyokika Gakkai Zasshi; 1995 Feb; 86(2):296-303. PubMed ID: 7534845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI-based prostate volume-adjusted prostate-specific antigen in the diagnosis of prostate cancer.
    Peng Y; Shen D; Liao S; Turkbey B; Rais-Bahrami S; Wood B; Karademir I; Antic T; Yousef A; Jiang Y; Pinto PA; Choyke PL; Oto A
    J Magn Reson Imaging; 2015 Dec; 42(6):1733-9. PubMed ID: 25946664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
    Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
    Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
    PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.